SCHEMBL678145

SCHEMBL678145

CC(=O)O[C@H](C)[C@H](N)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.50
TSHR P16473 2/20 0.46
SLC1A3 P43003 4/20 0.43
SLC1A2 P43004 4/20 0.43
SLC1A1 P43005 4/20 0.43
CASR P41180 1/20 0.38
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM1 P11229 1/20 0.35
TBXA2R P21731 1/20 0.35
GALR3 O60755 1/20 0.34
MAPT P10636 1/20 0.34
BLM P54132 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TP53 P04637 1/20 0.33
ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL678144 1.00 SLC7A5 (0.50) SLC7A5TSHRSLC1A3SLC1A2SLC1A1
SCHEMBL3449733 1.00 SLC7A5 (0.50) SLC7A5TSHRSLC1A3SLC1A2SLC1A1
SCHEMBL22266592 0.86 SLC7A5 (0.46) SLC7A5TSHRSLC1A3SLC1A2SLC1A1
SCHEMBL9980804 0.84 NOS3 (0.44) SLC7A5TSHRSLC1A3SLC1A2SLC1A1
SCHEMBL420691 0.83 TSHR (0.48) SLC7A5TSHRSLC1A3SLC1A2SLC1A1
SCHEMBL28327923 0.83 SLC7A5 (0.52) SLC7A5SLC1A3SLC1A2SLC1A1CASR
SCHEMBL684104 0.83 TSHR (0.48) SLC7A5TSHRSLC1A3SLC1A2SLC1A1
Alanine SCHEMBL15322896 0.82 SLC7A5 (0.35) SLC7A5TSHRSLC1A3SLC1A2SLC1A1
SCHEMBL6249367 0.82 SLC7A5 (0.46) SLC7A5TSHRSLC1A3SLC1A2SLC1A1
SCHEMBL17351893 0.81 TSHR (0.46) SLC7A5TSHRCHRM2CHRM4CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240418701-A1 SINGLE MOLECULE IDENTIFICATION WITH A REACTIVE HETERO-NANOPORE NANJING UNIVERSITY (CN) 2024-12-19 US claimed
EP-4413379-A1 SINGLE MOLECULE IDENTIFICATION WITH A REACTIVE HETERO-NANOPORE Nanjing University (CN) 2024-08-14 EP claimed
CN-118103711-A Single molecule identification with reactive heterogeneous nanopores 南京大学 2024-05-28 CN claimed
WO-2023056960-A1 SINGLE MOLECULE IDENTIFICATION WITH A REACTIVE HETERO-NANOPORE NANJING UNIVERSITY (CN) 2023-04-13 WO claimed
CN-113788877-A Novel insect kinin analogs and application thereof in aphid control 中国农业大学 2021-12-14 CN claimed
US-9090669-B2 Short fatty acid tail polymyxin derivatives and uses thereof NORTHERN ANTIBIOTICS LTD. (FI) 2015-07-28 US claimed
US-8940791-B2 Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements SIGNATURE R&D HOLDINGS, LLC (US) 2015-01-27 US claimed
US-20140200256-A1 Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements SIGNATURE R&D HOLDINGS, LLC (US) 2014-07-17 US claimed
US-20140142030-A1 SHORT FATTY ACID TAIL POLYMYXIN DERIVATIVES AND USES THEREOF NORTHERN ANTIBIOTICS LTD. (FI) 2014-05-22 US claimed
US-8642535-B2 Short fatty acid tail polymyxin derivatives and uses thereof NORTHERN ANTIBIOTICS LTD. (FI) 2014-02-04 US claimed
US-20120283176-A1 SHORT FATTY ACID TAIL POLYMYXIN DERIVATIVES AND USES THEREOF NORTHERN ANTIBIOTICS LTD. (FI) 2012-11-08 US claimed
US-8003683-B2 Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements SIGNATURE R&D HOLDINGS, LLC (US) 2011-08-23 US claimed
US-20070112060-A1 Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements SIGNATURE R&D HOLDINGS, LLC 2007-05-17 US claimed
US-20260125418-A1 A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT OWLSTONE MED LTD (GB) 2026-05-07 US disclosed
US-20260034237-A1 LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME GENMAB AS (DK) 2026-02-05 US disclosed
EP-4598592-A1 A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT Owlstone Medical Limited (GB) 2025-08-13 EP disclosed
EP-0626174-A2 Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1994-11-30 EP disclosed
EP-0552417-A1 Cyclic peptides and use thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-07-28 EP disclosed
EP-0528312-A2 Cyclic peptides and use thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-02-24 EP disclosed
US-4740611-A N,N'-disubstituted ureas THE STANDARD OIL COMPANY (US) 1988-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034237-A1 LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME CSGALNACT1, SLC43A1, OSTC SLC7A5 54/4885TSHR 389/4885SLC1A3 46/4885
US-20260125418-A1 A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT BRCA1, L3MBTL1, LMNA SLC7A5 1833/4885TSHR 2719/4885SLC1A3 3087/4885
US-20140200256-A1 Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements PLTP, GP6, PDGFA SLC7A5 500/4885TSHR 3362/4885SLC1A3 591/4885
US-20070112060-A1 Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements PLTP, GP6, PDGFA SLC7A5 500/4885TSHR 3362/4885SLC1A3 591/4885
US-20140142030-A1 SHORT FATTY ACID TAIL POLYMYXIN DERIVATIVES AND USES THEREOF VIP, ELOVL5, TLR5 SLC7A5 178/4885TSHR 4653/4885SLC1A3 4004/4885
US-20120283176-A1 SHORT FATTY ACID TAIL POLYMYXIN DERIVATIVES AND USES THEREOF ELOVL5, TLR5, VIP SLC7A5 179/4885TSHR 4693/4885SLC1A3 3910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.